{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:12:15Z","timestamp":1772899935468,"version":"3.50.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA221747"],"award-info":[{"award-number":["P50CA221747"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Experts and generalists from numerous clinical disciplines are likely to encounter and be involved in the care of patients with neurogenetic tumor syndromes. Considerations for genetic testing are discussed. Specific conditions including neurofibromatosis type 1, neurofibromatosis type 2-related schwannomatosis, von Hippel-Lindau disease, tuberous sclerosis, Lynch syndrome, Turcot syndrome, Li-Fraumeni syndrome, and others are reviewed. A variety of targeted therapies which have received regulatory approval for these disorders are described and promising future directions for therapeutics are highlighted.<\/jats:p>","DOI":"10.1093\/nop\/npaf089","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T11:43:58Z","timestamp":1755863038000},"page":"14-22","source":"Crossref","is-referenced-by-count":0,"title":["Neurogenetic tumor syndromes: The current landscape of workup and treatment"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-5396","authenticated-orcid":false,"given":"Rimas V","family":"Lukas","sequence":"first","affiliation":[{"name":"Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Northwestern University , Chicago, Illinois ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Cannon","sequence":"additional","affiliation":[{"name":"Department of Clinical and Diagnostic Sciences, University of Alabama at Birmingham , Birmingham, Alabama ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9349-4756","authenticated-orcid":false,"given":"Prashant","family":"Chittiboina","sequence":"additional","affiliation":[{"name":"National Institute of Health, Surgical Neurology Branch , Bethesda, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harish N","family":"Vasudevan","sequence":"additional","affiliation":[{"name":"Departments of Radiation Oncology and Neurological Surgery, University of California-San Francisco , San Francisco, California ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaishri O","family":"Blakeley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela C","family":"Hirbe","sequence":"additional","affiliation":[{"name":"Division of Oncology, Washington University , St Louis, Missouri ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"3","key":"2026030616171452000_CIT0001","first-page":"172","article-title":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, MD., USA, July 13-15, 1987","volume":"1","year":"1988","journal-title":"Neurofibromatosis."},{"issue":"8","key":"2026030616171452000_CIT0002","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation","volume":"23","author":"Legius","year":"2021","journal-title":"Genet Med."},{"issue":"1","key":"2026030616171452000_CIT0003","first-page":"vdaa153","article-title":"New developments in neurofibromatosis type 2 and vestibular schwannoma","volume":"3","author":"Ren","year":"2020","journal-title":"Neurooncol. Adv.."},{"issue":"11","key":"2026030616171452000_CIT0004","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/jnnp-2018-318538","article-title":"Schwannomatosis: a genetic and epidemiological study","volume":"89","author":"Evans","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"9","key":"2026030616171452000_CIT0005","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.gim.2022.05.007","article-title":"Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation","volume":"24","author":"Plotkin","year":"2022","journal-title":"Genet Med."},{"key":"2026030616171452000_CIT0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina","year":"2015","journal-title":"Handb Clin Neurol"},{"issue":"6","key":"2026030616171452000_CIT0007","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3171\/2021.3.JNS204203","article-title":"Hemangioblastoma diagnosis and surveillance in von Hippel-Lindau disease","volume":"136","author":"Huntoon","year":"2021","journal-title":"J Neurosurg."},{"issue":"5","key":"2026030616171452000_CIT0008","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/NRL.0000000000000085","article-title":"Neurological management of Von Hippel-Lindau disease","volume":"21","author":"Hodgson","year":"2016","journal-title":"Neurologist"},{"key":"2026030616171452000_CIT0009","doi-asserted-by":"crossref","first-page":"16035","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"2026030616171452000_CIT0010","article-title":"Lynch syndrome","volume-title":"GeneReviews","author":"Idos","year":"1993-2024"},{"issue":"12","key":"2026030616171452000_CIT0011","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1038\/s41431-024-01708-6","article-title":"ERN GENTURIS guidelines on constitutional mismatch repair deficiency diagnosis, genetic counseling, surveillance, quality of life, and clinical management","volume":"32","author":"Colas","year":"2024","journal-title":"Eur J Hum Genet."},{"issue":"9","key":"2026030616171452000_CIT0012","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","article-title":"Biochemical and imaging surveillance in germline TP53 mutation carriers with Li Fraumeni syndrome: 11 year follow up of a prospective observational study","volume":"17","author":"Villani","year":"2016","journal-title":"Lancet Oncol."},{"issue":"17","key":"2026030616171452000_CIT0013","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"Uusitalo","year":"2016","journal-title":"J Clin Oncol."},{"issue":"8","key":"2026030616171452000_CIT0014","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol."},{"issue":"21","key":"2026030616171452000_CIT0015","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-24-1611","article-title":"Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis type 1, Noonan syndrome, CBL syndrome, Costello syndrome, and related RASopathies","volume":"30","author":"Perrino","year":"2024","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2026030616171452000_CIT0016","doi-asserted-by":"crossref","first-page":"e20190660","DOI":"10.1542\/peds.2019-0660","article-title":"Health supervision for children with neurofibromatosis type 1","volume":"143","author":"Miller","year":"2019","journal-title":"Pediatrics."},{"issue":"1","key":"2026030616171452000_CIT0017","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1530\/ERC-13-0308","article-title":"Calculating optimal surveillance for detection of von Hippel-Lindau-related manifestations","volume":"21","author":"Kruizinga","year":"2014","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"2026030616171452000_CIT0018","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-0004.2009.01281.x","article-title":"Surveillance in von Hippel-Lindau disease (vHL)","volume":"77","author":"Poulsen","year":"2010","journal-title":"Clin Genet."},{"key":"2026030616171452000_CIT0019","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-31512-6_81-1","article-title":"Familial syndromes","volume-title":"Textbook of Pediatric Neurosurgery.","author":"Ferry","year":"2018"},{"issue":"11","key":"2026030616171452000_CIT0020","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2026030616171452000_CIT0021","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1086\/320121","article-title":"Mortality in neurofibromatosis 1: an analysis using U.S. death certificates","volume":"68","author":"Rassmussen","year":"2001","journal-title":"Am J Hum Genet."},{"issue":"3","key":"2026030616171452000_CIT0022","doi-asserted-by":"crossref","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026030616171452000_CIT0023","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/neuros\/nyaa455","article-title":"Genetic events and signaling mechanisms underlying Schwann cell fate in development and cancer","volume":"88","author":"Vasudevan","year":"2021","journal-title":"Neurosurgery."},{"issue":"11","key":"2026030616171452000_CIT0024","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/ng.3116","article-title":"Somatic mutations of SUZ12 in malignant peripheral nerve sheath tumors","volume":"46","author":"Zhang","year":"2014","journal-title":"Nat Genet."},{"issue":"11","key":"2026030616171452000_CIT0025","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","journal-title":"Nat Genet."},{"issue":"1","key":"2026030616171452000_CIT0026","first-page":"vdaa131","article-title":"Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival","volume":"2","author":"Lucas","year":"2020","journal-title":"Neurooncol. Adv.."},{"issue":"2","key":"2026030616171452000_CIT0027","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/ajmg.a.33139","article-title":"Birth incidence and prevalence of tumor-prone syndromes: evidence from a UK family genetic register service","volume":"152A","author":"Evans","year":"2010","journal-title":"Am J Med Genet A."},{"issue":"4","key":"2026030616171452000_CIT0028","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci USA."},{"issue":"5","key":"2026030616171452000_CIT0029","first-page":"514","article-title":"Mutation and cancer: neuroblastoma and pheochromocytoma","volume":"24","author":"Knudson","year":"1972","journal-title":"Am J Hum Genet."},{"issue":"9","key":"2026030616171452000_CIT0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrc885","article-title":"Molecular basis of the VHL hereditary cancer syndrome","volume":"2","author":"Kaelin","year":"2002","journal-title":"Nat Rev Cancer."},{"issue":"5","key":"2026030616171452000_CIT0031","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3171\/2014.1.JNS131431","article-title":"Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease","volume":"120","author":"Lonser","year":"2014","journal-title":"J Neurosurg."},{"issue":"2","key":"2026030616171452000_CIT0032","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3171\/jns.2006.105.2.248","article-title":"Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment","volume":"105","author":"Ammerman","year":"2006","journal-title":"J Neurosurg."},{"issue":"10","key":"2026030616171452000_CIT0033","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1586\/ern.11.124","article-title":"Management of von Hippel-Lindau disease-associated CNS lesions","volume":"11","author":"Wind","year":"2011","journal-title":"Expert Rev Neurother."},{"issue":"22","key":"2026030616171452000_CIT0034","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med."},{"issue":"5","key":"2026030616171452000_CIT0035","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/neuonc\/noac234","article-title":"Neurological applications of belzutifan in von Hippel-Lindau disease","volume":"25","author":"Zhang","year":"2023","journal-title":"Neuro Oncol"},{"issue":"10","key":"2026030616171452000_CIT0036","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(24)00389-9","article-title":"Belzutifan for patients with von Hippel-Lindau disease-associated CNS hemangioblastomas (LITESPARK-004): a multicentre, single arm, phase 2 study","volume":"25","author":"Iliopoulos","year":"2024","journal-title":"Lancet Oncol."},{"issue":"4","key":"2026030616171452000_CIT0037","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"5307","key":"2026030616171452000_CIT0038","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1126\/science.275.5307.1787","article-title":"Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC","volume":"275","author":"Morin","year":"1997","journal-title":"Science."},{"issue":"11","key":"2026030616171452000_CIT0039","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1093\/carcin\/bgl093","article-title":"Increased frequency of disease-causing MYH mutations in colon cancer families","volume":"27","author":"Peterlongo","year":"2006","journal-title":"Carcinogenesis."},{"issue":"9861","key":"2026030616171452000_CIT0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet."},{"issue":"6","key":"2026030616171452000_CIT0041","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"Franz","year":"2015","journal-title":"Ann Neurol."},{"issue":"9","key":"2026030616171452000_CIT0042","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsattelite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maoi","year":"2022","journal-title":"Ann Oncol."},{"issue":"26","key":"2026030616171452000_CIT0043","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"Donbi","year":"2016","journal-title":"N Engl J Med."},{"issue":"15","key":"2026030616171452000_CIT0044","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetenib in children with inoperable plexiform neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med."},{"issue":"6","key":"2026030616171452000_CIT0045","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"Moertel","year":"2025","journal-title":"J Clin Oncol."},{"issue":"1","key":"2026030616171452000_CIT0046","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41467-024-44755-9","article-title":"Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance","volume":"15","author":"Vasudevan","year":"2024","journal-title":"Nat Commun."},{"issue":"24","key":"2026030616171452000_CIT0047","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa2400985","article-title":"Brigatinib in NF2-related schwannomatosis with progressive tumors","volume":"390","author":"Plotkin","year":"2024","journal-title":"N Engl J Med."},{"issue":"2","key":"2026030616171452000_CIT0048","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-024-04613-6","article-title":"Virtual multi-institutional tumor board: a strategy for personalized diagnoses and management of rare CNS tumors","volume":"167","author":"Rogers","year":"2024","journal-title":"J Neurooncol."}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/nop\/advance-article-pdf\/doi\/10.1093\/nop\/npaf089\/64159921\/npaf089.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/1\/14\/64159921\/npaf089.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/nop\/article-pdf\/13\/1\/14\/64159921\/npaf089.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T21:17:26Z","timestamp":1772831846000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/13\/1\/14\/8243819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,28]]},"published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npaf089","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,8,28]]}}}